Recent developments in the management of severe asthma

Fevipiprant is unlikely to be implemented as a future treatment for severe asthma, while tezepelumab may be a future treatment option for patients with severe asthma with and without eosinophilic inflammation https://bit.ly/3KE1BH4

Detalles Bibliográficos
Autores principales: Meteran, Howraman, Tønnesen, Louise Lindhardt, Sivapalan, Pradeesh, Ingebrigtsen, Truls Sylvan, Jensen, Jens-Ulrik Stæhr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2022
Materias:
Journal Club
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584584/
https://www.ncbi.nlm.nih.gov/pubmed/36338257
http://dx.doi.org/10.1183/20734735.0178-2021
_version_ 1784813300695957504
author Meteran, Howraman
Tønnesen, Louise Lindhardt
Sivapalan, Pradeesh
Ingebrigtsen, Truls Sylvan
Jensen, Jens-Ulrik Stæhr
author_facet Meteran, Howraman
Tønnesen, Louise Lindhardt
Sivapalan, Pradeesh
Ingebrigtsen, Truls Sylvan
Jensen, Jens-Ulrik Stæhr
author_sort Meteran, Howraman
collection PubMed
description Fevipiprant is unlikely to be implemented as a future treatment for severe asthma, while tezepelumab may be a future treatment option for patients with severe asthma with and without eosinophilic inflammation https://bit.ly/3KE1BH4
format Online
Article
Text
id pubmed-9584584
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher European Respiratory Society
record_format MEDLINE/PubMed
spelling pubmed-95845842022-11-04 Recent developments in the management of severe asthma Meteran, Howraman Tønnesen, Louise Lindhardt Sivapalan, Pradeesh Ingebrigtsen, Truls Sylvan Jensen, Jens-Ulrik Stæhr Breathe (Sheff) Journal Club Fevipiprant is unlikely to be implemented as a future treatment for severe asthma, while tezepelumab may be a future treatment option for patients with severe asthma with and without eosinophilic inflammation https://bit.ly/3KE1BH4 European Respiratory Society 2022-03 2022-05-10 /pmc/articles/PMC9584584/ /pubmed/36338257 http://dx.doi.org/10.1183/20734735.0178-2021 Text en Copyright ©ERS 2022 https://creativecommons.org/licenses/by-nc/4.0/Breathe articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
spellingShingle Journal Club
Meteran, Howraman
Tønnesen, Louise Lindhardt
Sivapalan, Pradeesh
Ingebrigtsen, Truls Sylvan
Jensen, Jens-Ulrik Stæhr
Recent developments in the management of severe asthma
title Recent developments in the management of severe asthma
title_full Recent developments in the management of severe asthma
title_fullStr Recent developments in the management of severe asthma
title_full_unstemmed Recent developments in the management of severe asthma
title_short Recent developments in the management of severe asthma
title_sort recent developments in the management of severe asthma
topic Journal Club
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584584/
https://www.ncbi.nlm.nih.gov/pubmed/36338257
http://dx.doi.org/10.1183/20734735.0178-2021
work_keys_str_mv AT meteranhowraman recentdevelopmentsinthemanagementofsevereasthma
AT tønnesenlouiselindhardt recentdevelopmentsinthemanagementofsevereasthma
AT sivapalanpradeesh recentdevelopmentsinthemanagementofsevereasthma
AT ingebrigtsentrulssylvan recentdevelopmentsinthemanagementofsevereasthma
AT jensenjensulrikstæhr recentdevelopmentsinthemanagementofsevereasthma

Ejemplares similares